Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines

Nunukova,Alena; Neradil,Jakub; Skoda,Jan; Jaros,Josef; Hampl,Ales; Sterba,Jaroslav; Veselska,Renata

doi:10.3892/ijmm.2015.2210

Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines

Authors:
- Alena Nunukova
- Jakub Neradil
- Jan Skoda
- Josef Jaros
- Ales Hampl
- Jaroslav Sterba
- Renata Veselska
View Affiliations

Affiliations: Department of Experimental Biology, Faculty of Science, Masaryk University, 61137 Brno, Czech Republic, Department of Histology and Embryology, Faculty of Medicine, Masaryk University, 61137 Brno, Czech Republic, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 61137 Brno, Czech Republic
Published online on: May 14, 2015 https://doi.org/10.3892/ijmm.2015.2210
Pages: 65-72
Copyright: © Nunukova et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD133 (also known as prominin-1) is a cell surface glycoprotein that is widely used for the identification of stem cells. Furthermore, its glycosylated epitope, AC133, has recently been discussed as a marker of cancer stem cells in various human malignancies. During our recent experiments on rhabdomyosarcomas (RMS), we unexpectedly identified an atypical nuclear localization of CD133 in a relatively stable subset of cells in five RMS cell lines established in our laboratory. To the best of our knowledge, this atypical localization of CD133 has not yet been proven or analyzed in detail in cancer cells. In the present study, we verified the nuclear localization of CD133 in RMS cells using three independent anti-CD133 antibodies, including both rabbit polyclonal and mouse monoclonal antibodies. Indirect immunofluorescence and confocal microscopy followed by software cross-section analysis, transmission electron microscopy and cell fractionation with immunoblotting were also employed, and all the results undeniably confirmed the presence of CD133 in the nuclei of stable minor subpopulations of all five RMS cell lines. The proportion of cells showing an exclusive nuclear localization of CD133 ranged from 3.4 to 7.5%, with only minor differences observed among the individual anti-CD133 antibodies. Although the role of CD133 in the cell nucleus remains unclear, these results clearly indicate that this atypical nuclear localization of CD133 in a minor subpopulation of cancer cells is a common phenomenon in RMS cell lines.

View Figures

View References

1	Corbeil D, Karbanová J, Fargeas CA and Jászai J: Prominin-1 (CD133): Molecular and cellular features across species. Adv Exp Med Biol. 777:3–24. 2013. View Article : Google Scholar
2	Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J Pathol. 229:355–378. 2013. View Article : Google Scholar
3	Friedman GK and Gillespie GY: Cancer stem cells and pediatric solid tumors. Cancers (Basel). 3:298–318. 2011. View Article : Google Scholar
4	Xia P: Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther. 9:102–111. 2014. View Article : Google Scholar
5	Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, Zitterbart K and Sterba J: Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer. 8:3002008. View Article : Google Scholar : PubMed/NCBI
6	Sana J, Zambo I, Skoda J, Neradil J, Chlapek P, Hermanova M, Mudry P, Vasikova A, Zitterbart K, Hampl A, et al: CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol (Amst). 34:303–318. 2011. View Article : Google Scholar
7	Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G and Vento R: Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol. 219:301–313. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone sarcomas contain CD133⁺ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
9	Walter D, Satheesha S, Albrecht P, Bornhauser BC, D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I, Koscielniak E, Gengler C, et al: CWS Study Group: CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 6:e195062011. View Article : Google Scholar
10	Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY and Friedman GK: CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer. 60:45–52. 2013. View Article : Google Scholar
11	Veselska R, Skoda J and Neradil J: Detection of cancer stem cell markers in sarcomas. Klin Onkol. 25:2S16–2S20. 2012.PubMed/NCBI
12	Dela Cruz FS: Cancer stem cells in pediatric sarcomas. Front Oncol. 3:1682013. View Article : Google Scholar : PubMed/NCBI
13	Satheesha S and Schafer BW: Cancer stem cells in pediatric sarcomas. Stem Cells and Cancer Stem Cells. Hayat MA: Springer; Dordrecht: pp. 111–126. 2014, View Article : Google Scholar
14	Cantile M, Collina F, D’Aiuto M, Rinaldo M, Pirozzi G, Borsellino C, Franco R, Botti G and Di Bonito M: Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: A case report. Tumori. 99:e245–e250. 2013.PubMed/NCBI
15	Huang M, Zhu H, Feng J, Ni S and Huang J: High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer. Dis Markers. 2015:9860952015. View Article : Google Scholar : PubMed/NCBI
16	Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T and Relichova J: Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer. 6:322006. View Article : Google Scholar : PubMed/NCBI
17	Bidlingmaier S, Zhu X and Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med Berl. 86:1025–1032. 2008. View Article : Google Scholar : PubMed/NCBI
18	Loja T, Chlapek P, Kuglik P, Pesakova M, Oltova A, Cejpek P and Veselska R: Characterization of a GM7 glioblastoma cell line showing CD133 positivity and both cytoplasmic and nuclear localization of nestin. Oncol Rep. 21:119–127. 2009.
19	Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G and Giordano A: Detection and characterization of CD133⁺ cancer stem cells in human solid tumours. PLoS One. 3:e34692008. View Article : Google Scholar
20	Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I and Moffat J: Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep. 2:951–963. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang SC and Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
22	Mills IG: Nuclear translocation and functions of growth factor receptors. Semin Cell Dev Biol. 23:165–171. 2012. View Article : Google Scholar
23	Carpenter G and Liao HJ: Receptor tyrosine kinases in the nucleus. Cold Spring Harb Perspect Biol. 5:a0089792013. View Article : Google Scholar : PubMed/NCBI
24	Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, Nakagawara A and Kamijo T: CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene. 30:97–105. 2011. View Article : Google Scholar
25	Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, et al: Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA. 110:6829–6834. 2013. View Article : Google Scholar : PubMed/NCBI
26	Shimozato O, Waraya M, Nakashima K, Souda H, Takiguchi N, Yamamoto H, Takenobu H, Uehara H, Ikeda E, Matsushita S, et al: Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene. 34:1949–1960. 2014. View Article : Google Scholar